News | September 21, 2010

U.S. Results Published for VAD

September 21, 2010 – Ventricular assist devices (VADs) can restore normal hemodynamics and support recovery of native cardiac function after acute myocardial infarction (AMI), according to a study published in the September 2010 issue of The Annals of Thoracic Surgery. The study looked at patients who used Abiomed’s AB5000 Ventricular Assist Device.

“This is the largest reported paper on AMI cardiogenic shock patients on VAD support. It demonstrates that aggressive and early implantation of bridge to recovery VADs, such as the AB5000, can potentially improve recovery and survival outcomes of cardiogenic shock patients,” said Mark Anderson, M.D., Robert Wood Johnson Medical School. “Recovery should be the first option. Though VAD support for AMI cardiogenic shock patients is not yet in the clinical guidelines, this paper shows that temporary heart recovery devices have the ability to recover heart muscle and avoid heart transplantation in these critically ill patients.”

Results
• The estimated survival rate for AMI cardiogenic shock patients, calculated using the Logistic EuroSCORE, is less than 15 percent. The actual survival rate for the same patient population in the AB5000 registry was 40 percent.
• Roughly two-thirds, or 63 percent, of the survivors experienced recovery of their native hearts. Recovery was defined as patients demonstrating stable unassisted cardiac function 30 days after VAD explant or at discharge.
• The survival for recovery patients at two years after VAD explant was 78 percent (Kaplan-Meier estimated).
• Of the survivors who stayed on AB5000 support and were not able to recover their native hearts, 80 percent were successfully transplanted and discharged.

The AB5000 registry in The Annals of Thoracic Surgery can be viewed at: http://ats.ctsnetjournals.org/cgi/content/full/90/3/706?maxtoshow=&hits=10&RESULTFORMAT=&author1=anderson&fulltext=ab5000&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT .

This paper can also be viewed as part of The Annals of Thoracic Surgery accredited CME program.

For additional information please visit: www.abiomed.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init